Hiding Behind Complexity: Supply Chain, Oversight, Race, and the Opioid Crisis
Preprint
- 1 January 2023
- preprint
- Published by Elsevier in SSRN Electronic Journal
Abstract
The opioid crisis has ravaged the United States taking 69,000 lives in 2020, with prescription opioids accounting for 98% of opioid abuse. Though nationally, this epidemic is often considered a White public health crisis, overdose deaths have doubled among people of color from 2017-2019. Significant public criticism has gone to several individual firms involved as research has demonstrated that the opioid crisis was driven by excessive supply from the pharmaceutical industry. We find evidence that the scope of the blame goes beyond individual actors to include the very structure of supply chains, where complex supply chains may have exacerbated the crisis by dispensing significantly more opioids. We posit that supply chain complexity allowed mass quantities of opioids to escape detection by the Drug Enforcement Administration (DEA). Further, we find new evidence showing the greater impact of complexity on dispensing in non-White communities, which underscores their exclusion from the public discourse and governmental response surrounding the crisis and suggests possible racial bias in the DEA’s regulatory policies. Our analysis was made possible by the hotly contested 2019 release of the DEA’s ARCOS database that logs every shipment in the supply chain of opioids in the United States from 2006-2014. Using a fixed effects model, we find that a one-unit increase across three dimensions of supply chain complexity is associated with a 16% increase in opioid dispensing. This effect is intensified in non-White communities, where a 10% increase in the non-White population is associated with a 3.39% (1.33%) increase in the effects of complexity for high (average) complexity supply chains. To verify that excess dispensing of high-complexity pharmacies supplied non-medical/recreational demand, we exploit the reformulation of OxyContin designed to prevent recreational use as an exogenous shock to the market. In a novel approach, we use the fact that different pharmacies received their first shipment of reformulated OxyContin at different times and use a difference-in-differences model to estimate the heterogeneous effect of the shock on dispensing. As the abuse-deterrent OxyContin stifled demand, high-complexity pharmacies experienced a 15.31% greater reduction in dispensing compared to lower-complexity pharmacies, suggesting the excess dispensing was satisfying non-medical/recreational demand.Keywords
This publication has 47 references indexed in Scilit:
- Impact of the U.S.–China trade war on the operating performance of U.S. firms: The role of outsourcing and supply base complexityJournal of Operations Management, 2022
- Difference-in-differences with variation in treatment timingJournal of Econometrics, 2021
- Difference-in-Differences with multiple time periodsJournal of Econometrics, 2021
- The association between supply chain structure and transparency: A large‐scale empirical studyJournal of Operations Management, 2021
- Supply base innovation and firm financial performanceJournal of Operations Management, 2020
- Is it too complex? The curious case of supply network complexity and focal firm innovationJournal of Operations Management, 2019
- Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related OverdosesJAMA Network Open, 2019
- Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United StatesJAMA Psychiatry, 2015
- Association Between Opioid Prescribing Patterns and Opioid Overdose-Related DeathsJAMA, 2011
- The Architecture of Complexity1991